Adding baricitinib to TPO-RA for hard-to-treat ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding baricitinib (a type of immune-modulating drug) to a standard platelet-boosting medication works better than the standard medication alone for adults with chronic ITP that hasn't responded to initial treatment. It aims to find a new option for people whose platelet counts remain low despite treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have ITP that did not improve after 2 weeks of a standard platelet-boosting medication (TPO-RA).
- Your platelet count is below 30, or between 30 and 50 with significant bleeding symptoms.
- You are not pregnant, planning pregnancy, or breastfeeding.
- You have not had a serious infection like shingles, tuberculosis, or hepatitis recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug (ripertamab) to a standard ITP treatment (eltrombopag) for patients whose platelet count hasn't improved with steroids. The goal is to see if the combination works better at raising platelet counts and lowering bleeding risk.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
This trial tests two ways to raise platelets for people with immune thrombocytopenia (ITP) who did not respond well to a short course of the platelet-boosting drug rhTPO. One group gets a higher dose of rhTPO, the other switches to a different oral medication, eltrombopag. The goal is to see which approach works better to increase platelet counts safely.
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.